Intravitreal bevacizumab(Avastin) for macular edema secondary to uveitis: 1 year results of a prospective pilot study
Not Applicable
- Conditions
- Macular edema secondary to uveitis.Other specified retinal disorders
- Registration Number
- IRCT138902113846N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
In a prospective clinical trial consecutive 30 patients with uveitis and CME will be enroll in the study. None of the patients will have a systemic or an ocular disease other than the one causing uveitis.
Patients with history of other diseases causing macular edema (such as diabetes mellitus and retinal vein occlusions) will be excluded from the study. All of the patients should have decreased vision due to Cystoid Macular Edema (CME),
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Central macular thickness. Timepoint: Before injection and 1, 3, 6 and 12 months after injection. Method of measurement: SD-OCT.;Best corrected visual acuity. Timepoint: Before injection and 1, 3, 6 and 12 months after injection. Method of measurement: Standard snelen chart and log mar.
- Secondary Outcome Measures
Name Time Method Complication of intravitreal injection of bevacizumab. Timepoint: During 1 year after injection. Method of measurement: Routine physical examination.